Holen Sie sich die Stockscreener-App
1.47
3.92%
-0.06
Handel nachbörslich:
1.47
Schlusskurs vom Vortag:
$1.53
Offen:
$1.55
24-Stunden-Volumen:
77,468
Relative Volume:
0.32
Marktkapitalisierung:
$137.46M
Einnahmen:
-
Nettoeinkommen (Verlust:
$1.60M
KGV:
49.00
EPS:
0.03
Netto-Cashflow:
$-62.91M
1W Leistung:
+1.38%
1M Leistung:
+5.00%
6M Leistung:
-7.55%
1J Leistung:
-32.88%
1-Tages-Spanne:
$1.45
$1.55
1-Wochen-Bereich:
$1.38
$1.555
52-Wochen-Spanne:
$1.13
$2.66
Compugen Ltd Stock (CGEN) Company Profile
Vergleichen Sie CGEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGEN
Compugen Ltd
|
1.47 | 135.59M | 0 | 1.60M | -62.91M | 0.03 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-13 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-05 | Herabstufung | Jefferies | Buy → Hold |
| 2020-05-26 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2020-05-13 | Eingeleitet | Stifel | Buy |
| 2020-05-07 | Eingeleitet | SVB Leerink | Outperform |
| 2020-04-22 | Eingeleitet | ROTH Capital | Buy |
| 2020-03-24 | Eingeleitet | SunTrust | Buy |
| 2020-01-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-03-29 | Eingeleitet | Oppenheimer | Outperform |
| 2016-02-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2015-10-15 | Eingeleitet | FBR Capital | Outperform |
| 2015-04-23 | Fortgesetzt | Jefferies | Buy |
| 2015-04-21 | Eingeleitet | Oppenheimer | Outperform |
| 2014-02-07 | Eingeleitet | MLV & Co | Buy |
| 2009-12-28 | Bestätigt | Cantor Fitzgerald | Buy |
| 2009-07-29 | Eingeleitet | Cantor Fitzgerald | Buy |
Alle ansehen
Compugen Ltd Aktie (CGEN) Neueste Nachrichten
Coeptis Therapeutics (NASDAQ:COEP) and Compugen (NASDAQ:CGEN) Head to Head Comparison - Defense World
Northern Trust Corp Raises Stock Position in Compugen Ltd. (NASDAQ:CGEN) - Defense World
These Analysts Just Made An Incredible Downgrade To Their Compugen Ltd. (NASDAQ:CGEN) EPS Forecasts - Yahoo Finance
Analysts Just Shaved Their Compugen Ltd. (NASDAQ:CGEN) Forecasts Dramatically - simplywall.st
Analysts Offer Predictions for Compugen FY2025 Earnings - Defense World
Q2 Earnings Forecast for Compugen Issued By Leerink Partnrs - Defense World
Compugen Ltd. (NASDAQ:CGEN) Q1 2025 Earnings Call Transcript - Insider Monkey
Compugen: Q1 Earnings Snapshot - New Haven Register
Compugen Ltd (CGEN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline - Yahoo Finance
Compugen’s Q1 2025: Clinical Progress and Financial Stability - TipRanks
Compugen earnings missed, revenue fell short of estimates By Investing.com - Investing.com South Africa
Compugen Q1 2025 Earnings Call Transcript - MarketBeat
Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Transcript : Compugen Ltd., Q1 2025 Earnings Call, May 19, 2025 - marketscreener.com
Compugen Ltd reports results for the quarter ended March 31Earnings Summary - TradingView
Compugen earnings missed, revenue fell short of estimates - Investing.com Australia
Compugen Reports Q1 2025 Results and Strategic Developments - TipRanks
Compugen Reports First Quarter 2025 Results | CGEN Stock News - GuruFocus
Compugen Reports First Quarter 2025 Results - Yahoo Finance
Compugen (CGEN) to Release Earnings on Monday - Defense World
COMPUGEN Earnings Preview: Recent $CGEN Insider Trading, Hedge Fund Activity, and More - Nasdaq
Compugen CEO Anat Cohen-Dayag to transition to executive chair - MSN
Raymond James Financial Inc. Acquires Shares of 67,041 Compugen Ltd. (NASDAQ:CGEN) - Defense World
Compugen (CGEN) Announces Leadership Transition for 2025 | CGEN Stock News - GuruFocus
Compugen Announces Leadership Transitions Effective September 2025 | CGEN Stock News - GuruFocus
Compugen Announces Leadership Transitions Effective September 2025 - marketscreener.com
Compugen Announces Leadership Transitions Effective September 20 - GuruFocus
Compugen Announces Leadership Changes Effective September 2025 - TipRanks
Compugen announces executive leadership changes By Investing.com - Investing.com India
Compugen announces executive leadership changes - Investing.com
Investor Network: Compugen Ltd. to Host Earnings Call - ACCESS Newswire
Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025 | CGEN Stock News - GuruFocus
Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025 - Yahoo Finance
Compugen Q1 2025 Earnings Call: Management to Present Latest Cancer Immunotherapy Progress May 19 - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
67,041 Shares in Compugen Ltd. (NASDAQ:CGEN) Acquired by Raymond James Financial Inc. - Defense World
Compugen (NASDAQ:CGEN) vs. Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) Financial Review - Defense World
Commonwealth Equity Services LLC Takes Position in Compugen Ltd. (NASDAQ:CGEN) - Defense World
Compugen Ltd. Announces Appointment of Alberto Sessa as Chief Financial Officer - marketscreener.com
Compugen at Stifel Forum: Strategic Insights on Immunotherapy Pipeline By Investing.com - Investing.com South Africa
Compugen at Stifel Forum: Strategic Insights on Immunotherapy Pipeline - Investing.com Australia
Is There An Opportunity With Compugen Ltd.'s (NASDAQ:CGEN) 33% Undervaluation? - simplywall.st
Compugen at Needham Conference: Strategic Immuno-Oncology Insights - Investing.com Australia
Compugen at Needham Conference: Strategic Immuno-Oncology Insights By Investing.com - Investing.com India
Compugen stock touches 52-week low at $1.35 amid market challenges - Investing.com Canada
Compugen stock touches 52-week low at $1.35 amid market challenges By Investing.com - Investing.com South Africa
Finanzdaten der Compugen Ltd-Aktie (CGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):